Tumors routinely attract and co-opt macrophages to promote their growth, angiogenesis and metastasis. Macrophages are also the key effector cell for monoclonal antibody (mAb) 
Introduction
Tumors can suppress the innate and adaptive arms of the immune system through regulation of myeloid cells (1, 2) . Central to this suppressive capacity is the regulation of macrophages. Macrophages that have differentiated through interaction with tumor cells play a key role in exerting local immunosuppression and promoting tumour metastasis, neoplastic invasion of ectopic tissue and angiogenesis (3) . Although the description of macrophage activation is currently contentious, these tumor promoting macrophages have been proposed to be akin to IL-4/-13 stimulated, anti-inflammatory "M2" macrophages generated during wound-healing which orchestrate Th2 responses and promote tissue repair and remodelling (4) . Polarisation of TAM towards an LPS/IFN-γ activated, inflammatory "M1" state provides the potential to arrest these tumor promoting activities and alleviate immunosuppression (5) .
Reagents capable of achieving this have the capacity to provide anti-tumor effects;
particularly as an adjuvant to immunotherapy and are keenly sought in cancer therapy (6) .
Toll-like receptor agonists (TLRa) are potent stimulators of innate immunity, acting as "danger" signals that elicit phenotypic, secretory and transcriptomic changes in macrophages consistent with immune activation (7, 8) . Several studies have shown that
TLRa can provide adjuvants effects in human cancers; TLR9a CpG was shown to be feasible, safe and powerful to induce objective clinical response in lymphoma patients (9) and TLR7a Imiquimod was effective in the treatment of vulvar intraepithelial neoplasia (10) .
Efficacy of TLRa in combination with monoclonal antibody (mAb) therapy in animal models has also been explored. Agonistic anti-CD40 mAb combined with Imiquimod induced a systemic anti-tumor CD8+ T cell and type I Interferon response, significantly delaying the growth of implanted tumors and prolonging animal survival in models of mesothelioma (11) and melanoma (12) . In our own studies (13) , we have shown that TLR3a
Polyinosinic:polycytidylic acid (Poly I:C) augmented the agonistic activity of anti-CD40 mAb dependent upon the upregulation of activating Fc-gamma receptors (FcγR). Although TLRa based reagents have been investigated in combination with antibody immunotherapy in humans (14) , and such studies have motivated ongoing trials, they are yet to be successfully translated into the clinic (15) .
Cyclic dinucleotides are a new class of immune adjuvants being evaluated in preclinical studies and in an early phase clinical trial in patients with advanced/metastatic solid tumors (NCT02675439).They signal via stimulator of interferon genes (STING), which is crucial for sensing DNA viruses (16, 17) . Cytosolic DNA activates STING, leading to phosphorylation of IRF3 via tank-binding kinase 1 (TBK1), and subsequent transcription of type I interferon genes (17) (18) (19) . In vivo studies have shown that STING -/-or IRF3 -/-mice fail to prime T cells against tumor antigens and do not reject immunogenic tumors (20) , emphasising a critical role for host STING in immune sensing of tumors through dendritic cell (DC) activation and T cell priming (21, 22) .
Here we document a comprehensive analysis of the efficacy of STING and TLR agonists in promoting macrophage pro-inflammatory activation, and tumoricidal function in combination with mAb immunotherapy. Certain TLRa were highly potent at activating both human and murine macrophages and augmenting antibody dependent cellular phagocytosis (ADCP) in vitro but did not elicit similar potency in murine in vivo models of normal and malignant B cell depletion. However, STINGa were potent both in vitro and in vivo, crucially reversing lymphoma-mediated immunosuppression and providing protection in tumor bearing mice where immunotherapy alone failed. STINGa but not TLRa were subsequently shown to effectively reverse the suppressive effects induced by the lymphoma on macrophage FcγR expression, the principal immune effector cells in vivo. 
Materials and Methods

Clinical Samples and Ethics
In vivo B cell depletion (adoptive transfer) assays
Splenocytes from target hCD20Tg (T) and non-target (NT) wild-type (unless otherwise specified) mice were labelled with 5μM and 0.5μM CFSE (Invitrogen), respectively, mixed once (300μg at 24h). Spleen was harvested 16-20h after Ritm2a administration, splenocytes stained with anti-mouse CD19 APC (eBioscience) and assessed for T:NT ratio. IFNAR blocking mAb (Clone MAR1-5A3; Leinco) was given at 500μg i.p as indicated in the figure legend.
Generation and polarisation of hMDM and mBMDM
hMDM and mBMDM were generated as described (23, 25 
hMDM and mBMDM phagocytosis assay and phagocytic index
Phagocytosis assay was performed as described (23, 25) . hCD20 transgenic murine B cells and human CLL cells were used as targets for mBMDM and hMDM respectively. 
BCL1 lymphoma model and therapy
On day 0, 8-12 week female WT or FcγR null BALB/c mice were injected in tail vein with 1x10 4 BCL1 tumor cells. DMXAA (300μg) and anti-CD20 18B12 (200μg, produced in-house from patented published sequences) were administered as indicated in Figure 7A . Anti-CD8
antibody YTS169 (500μg, in-house) was injected i.p on day 0, 5, 10 and 14. Tumor bearing mice were culled humanely before reaching terminal endpoint.
Chemokine and cytokine gene expression
RNA was purified from mice spleen using Qiagen RNAeasy mini kit. 500ng RNA was used to synthesise cDNA using RT 2 First Strand Kit and gene expression was assessed using RT 2 Profiler PCR mouse cytokine and chemokine array kit (Qiagen).
Statistical analysis
Statistical analysis was performed using GraphPadPrism. To compare differences between the experimental groups, student's t test, Wilcoxon, paired or unpaired t test analyses were performed; Kaplan Meier curves were produced and analysed by Log rank (Mantel-Cox) test.
A P-value <0·05 was considered significant at the 95% confidence interval. Stars denote significance as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Results
Tumors can generate a suppressive microenvironment with a low FcγR A:I ratio on macrophages leading to mAb therapy resistance
To explore how tumors can regulate their microenvironment in vivo, we performed adoptive transfer experiments (24) in mice harbouring the syngeneic mouse lymphoma, BCL1 (27) .
The ability of the anti-human CD20 mAb, Ritm2a to deplete adoptively transferred target human CD20 transgenic (hCD20 Tg) B cells was examined (24) . Whereas depletion of target cells was efficient in mice lacking tumor, in mice implanted with even low numbers Fig   S1B) . These data illustrate the profound effects that the tumor can elicit on macrophage
FcγR expression profiles and phenotypic markers culminating in a substantially lowered A:I ratio and resistance to antibody mediated target cell depletion (Fig. 1A) ; even when very few tumor cells were detectable (e.g. at day 7 and 14). Notably, and in accordance with their redundancy in mediating target cell clearance in the adoptive transfer model (Supplementary
Fig. S1C-E), monocytes and neutrophils did not show such profound changes in their FcγR
A:I ratios (Fig. 1E ).
The inhibitory FcγRII has been previously shown to suppress antibody-mediated depletion (33) . We therefore assessed the contribution of elevated FcγRII levels to the defective mAb depletion in our system. We found that FcγRII knockout mice harbouring BCL1 lymphoma treated with anti-CD20 mAb demonstrated enhanced (~50%) deletion of target cells compared to WT mice (Fig 1F) . These results show that a significant proportion, but not all of the effects of the tumor immune suppression is due to elevations in FcγRII and that strategies to enhance FcγR A:I would likely augment mAb activity.
FcγR changes induced in murine bone marrow derived macrophages (mBMDM) by
TLRa and STINGa
Having established that FcγR profiles and A:I ratios on TAM were the key determinants of mAb-mediated target cell deletion, we sought to identify suitable TLR and STING ligand reagents capable of modifying these properties. The majority of TLRa tested did not show any activity with mBMDM, either in terms of modulating FcγR expression ( Fig. 2A) , increasing the FcγR A:I ratio (Fig. 2B ) or augmenting phagocytosis (Fig. 2C) . The sole exception was TLR3a (Poly I:C) which typically showed an increase in FcγR A:I ratio coincident with an increase in phagocytosis ( Fig. 2B and C) . In contrast to TLRa, both human (2'2'-, 2'3'-and 3'3'-cGAMP) and murine (DMXAA) STINGa showed increases in expression of activating FcγRs I, III and IV with no changes in FcγRII ( Fig. 2A) , culminating in an increased FcγR A:I ratio (Fig. 2B) , and significant increases in phagocytosis ( Fig. 2C and Supplementary Fig. S2 ). Notably, we observed a correlation between phagocytic activity of macrophages with their FcγR A:I ratio (Fig. 2D , R 2 =0.48, p=0.0041).
Stimulation of mBMDM with STINGa also induced potent type I Interferon-α and -β responses, with TLR3a again being the only TLRa to induce the secretion of these cytokines (Fig. 2E ).
Phenotypic and cytokine changes induced in human monocyte derived macrophage (hMDM) stimulated with TLRa or STINGa
We next examined whether our observations pertaining to mouse macrophages could be translated to human. We first established that hMDM stimulated with TLRa displayed changes in a range of phenotypic markers; CD40, CD80, CD14, MHCII, CD206 and CD11b that were akin to changes induced by LPS/IFN-γ treatment ( Supplementary Fig S3) . We then investigated responses to a broader panel of both TLR and STINGa for their ability to induce phenotypic changes in hMDM in relation to the representative markers CD40, CD38 and CD11b. CD40 and CD38 are considered markers of immune cell activation and are generally upregulated on macrophages following stimulation with LPS (34, 35) . Accordingly, CD40 and CD38 were significantly upregulated in hMDM stimulated with LPS/IFN-γ and decreased following IL-4/-13 treatment. Although the integrin αmβ2 (CD11b) is generally considered a pan-macrophage marker, its expression was significantly decreased with LPS/IFN-γ and increased with IL-4/-13 ( Fig. 3A and 3B ). Consistent with an activated pro-inflammatory profile, supernatant from hMDM stimulated with TLRa contained elevated IFN-γ, IL-6, IL-12p70 and TNF-α, comparable to supernatant from LPS/IFN-γ stimulated macrophages (Fig. 3C) . However, such cytokine responses were not seen following stimulation with STINGa; instead supernatant from STINGa 2'2'-and 2'3'-cGAMP treated macrophages displayed a type I interferon cytokine profile with release of both IFN-α and IFN-β (Fig. 3D ), thereby demonstrating a divergence in STING and TLR inflammatory signalling with respect to cytokine induction in human myeloid cells.
FcγR changes and phagocytic activity of hMDM stimulated with TLRa or STINGa
We subsequently examined the expression pattern of activating (FcγRI, -IIA, -III) and inhibitory (FcγRIIB) FcγR on hMDM stimulated with TLRa or STINGa (Fig. 4A) ; and calculated the A:I ratio (Fig. 4B) . TLRa -1/2, -5 and -7/8 showed an increase in the expression of activating FcγRs and decrease in inhibitory FcγRIIB resulting in an increased A:I ratio (Fig. 4 A-B) , similar to LPS/IFN-γ polarised macrophages. STINGa 2'2' and 2'3' -cGAMP also resulted in an increase in the expression of activatory receptors FcγRIIA and FcγRIII, and a decrease in FcγRIIB, resulting in a statistically significant increase in A:I ratio ( Fig. 4B and Supplementary Fig. S4A ). In contrast, we observed a decrease in A:I ratio with IL-4/-13 polarised macrophages, largely mediated through an upregulation in FcγRIIB.
The phenotypic changes, cytokine profile and FcγR changes of hMDM treated with TLRa and STINGa were indicative of pro-inflammatory tumoricidal effectors. We therefore assessed if these cells also displayed augmented functional activity in terms of their ability to phagocytose antibody-opsonised CLL cells ( Fig. 4C and Supplementary Fig S4B) . (Fig. 5A) . Intriguingly, the TLRa 1/2 that was potent with hMDM in vitro failed to enhance target B cell depletion in mice in vivo and appeared to be inhibitory. We next investigated the differences in FcγR expression and A:I ratio induced on splenic macrophages following TLRa -1/2 and -3 treatment (Fig. 5B) . No significant change in FcγR A:I ratio was observed in macrophages from TLR1/2a treated mice, whilst TLR3a induced a significant increase in FcγR A:I ratio, likely explaining the elevated depletion with this reagent.
Whilst TLR3a mediated a modest increase in the depletion of adoptively-transferred target B cells in these experiments, the murine STING ligand DMXAA mediated a dramatic ~90% depletion of target B cells in combination with Ritm2a (Fig. 5C) . We also observed a statistically significant, four-fold increase in the FcγR A:I ratio on splenic macrophages of mice that were primed with DMXAA compared to naïve mice ( Fig. 5D ) demonstrating that amongst all reagents assessed, DMXAA was the most potent in both upregulating the A:I ratio and depleting target B cells.
The adoptive transfer experiments discussed above provided a robust model to study target B cell depletion in the absence of any complexity arising from a suppressive tumor microenvironment. However, when BCL1 cells were inoculated into recipient mice 1 week prior to adoptive transfer, the most potent TLRa Poly I:C failed to induce mAb target cell deletion, whilst DMXAA retained its efficacy even in the presence of the tumor (Fig. 5E ). This DMXAA effect on Ritm2a activity was an antibody Fc dependent process as FcR γ chain KO mice, devoid of activatory FcγRs, were unable to delete target B cells in the same setting (Fig. 5E ). When splenic macrophages from TLR3a or DMXAA treated tumor bearing mice were assessed for FcγR changes, we found that DMXAA but not TLR3a was able to completely reverse the suppressive effect of the tumor on the macrophage FcγR A:I ratio (Fig. 5F ). Hence, the observed changes in FcγR A:I ratios provide an explanation as to why TLR3a loses its efficacy in tumor bearing hosts but DMXAA retains its ability to enhance mAb mediated B cell depletion even within an immunosuppressive tumor microenvironment.
We were also able to exclude that this augmented deletion of target cells in the presence of tumor microenvironment was the result of any direct cytotoxic effect of DMXAA, as the percentage of both tumor and non-tumor B cells retrieved 24 hours after DMXAA injection into BCL1-bearing mice was equivalent to that of mice not treated with DMXAA (Fig. 5G) .
Notably, administration of DMXAA induced upregulation of type I IFN gene expression and also reduced expression of both IL-10 and IL-21 that were upregulated following inoculation of the tumor (Supplementary Fig S5) .
Type I IFN elicits macrophage FcγR skewing and augments mAb target cell deletion
In both human and murine cells, STINGa induced type I IFN (Fig 2-3, S5 ). Type I IFN is a key downstream mediator of STING activation (18), and therefore we interrogated if type I IFN were also able to modulate FcγR A:I ratio changes and target B cell deletion. We found that in hMDM, type I IFN induced upregulation of FcγRIIA and III leading to an increase in A:I ratio and phagocytosis of target CLL cells, in a manner similar to that mediated by STINGa (Fig 6A) . Likewise, administration of type I IFN to mice led to a significant increase in splenic macrophage FcγR A:I ratio, mostly mediated by an increase in FcγRIV, as seen with DMXAA ( Fig 6B) . mBMDM incubated in the presence of type I IFN also phagocytosed target cells more effectively, with a phagocytic index comparable to STINGa treated mBMDM (Fig 6B) .
Furthermore, Ritm2a-mediated deletion of target B cells in adoptive transfer assays were also significantly enhanced in mice that were primed with type I IFN prior to mAb administration ( Fig 6C) . Most importantly, the target B cell deleting ability of DMXAA was completely abrogated in mice that received IFNAR blocking antibody, further strengthening the role of type I IFN in downstream mechanisms governing the STING-mediated effects (Fig 6D) .
STINGa DMXAA enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner
Finally, having established that STING activation was capable of overcoming a suppressive lymphoma microenvironment to delete normal B cells in a transplant system, we assessed if the same approach could provide effective deletion of the malignant B cells themselves in a therapy model. BCL1 bearing mice were treated with anti-mouse CD20 mAb (18B12) (38) in the presence or absence of DMXAA as depicted in Fig. 7A . When we monitored FcγR modulation in the therapy model, we observed that the tumor substantially downregulated activatory FcγRI and caused a dramatic increase in the inhibitory FcγRII. Both of these changes were reversed by DMXAA, which also induced a four-fold increase in FcγRIII and IV (Fig. 7B) ; allowing DMXAA to reverse the A:I changes induced by the lymphoma microenvironment (Fig. 7C ). This was reflected in the survival of experimental animals: anti-CD20 and DMXAA monotherapies produced modest therapeutic effects whereas ≥ 90% of mice that were primed with DMXAA prior to anti-CD20 administration were effectively cured, surviving for longer than 100 days (Fig. 7D ). This significant enhancement in tumor protection over anti-CD20 (median survival 36 days; p<0.0001) or DMXAA alone (median survival 32 days; p<0.0001) produced by the combination therapy was lost when mice were devoid of FcγRs (FcγR-null; median survival 30 days; Fig. 7E ) showing that modulation of FcγRs is crucial to the combination effect. In contrast, the induction of an adaptive cytotoxic CD8 + T cell response is not required as 100% of mice receiving the combination therapy following CD8 + T cell depletion were also cured (Fig. 7F) .
Discussion
TAM are typically immunosuppressive and have the capacity to negatively impact on anticancer immunotherapy strategies. Although deletion of TAM could overcome this issue, it will also impede tumor cell clearance with direct targeting antibodies, which rely on macrophages for their mode of action (24, 31) and are an important component of lymphoma treatment. Therefore, an alternative approach to restrict or prevent tumor growth and yet retain or provide an increased capacity of the TAM to deliver immunotherapy treatments is highly desired (39).
Here we identify that lymphoma cells can elicit a microenvironment that is profoundly suppressive, leading to resistance to mAb-mediated deletion of target cells and therapy. mAb and lymphoma, these changes appear to be more important in the macrophage population, as both monocytes and neutrophils were relatively unaffected by the tumor.
We demonstrate that the majority of TLRa tested polarised hMDM towards an activated phenotype, including an enhanced FcγR A:I ratio, induced a broad, pro-inflammatory cytokine response, and augmented their mAb-mediated phagocytic activity; all parameters desirable for anti-tumor immunity and yet had more modest effects on mBMDMs. The reasons for this are currently unclear but may reflect established species-specific differences (37) . Alternatively, these differences may be attributed to the alternative progenitors from which the macrophages were generated (i.e. peripheral blood monocytes versus bone marrow precursors). Conversely, STINGa elicited more reproducible changes in FcγR, and type I IFN production, in both hMDM and mBMDM, effectively augmenting ADCP and performed consistently in murine assays both in vitro and in vivo. FcγR modulation is likely to be an important mechanism behind the activity of STINGa in vivo as its activity was completely abrogated in  chain -/-mice lacking activating FcγR. Furthermore, the enhanced B cell depleting activity induced by STINGa was directly correlated with an enhanced A:I ratio, both in non-tumor and tumor bearing adoptive transfer assays. A principal finding of our study was the impressive potency of STINGa in augmenting macrophage activation and mAb-mediated effector mechanisms both in vitro and in vivo.
Although the STINGa DMXAA showed very impressive effects in the murine lymphoma model studied here, early human cancer trials using DMXAA failed (48) . Subsequent studies revealed that this was due to an inability of DMXAA to activate human STING (49 
